{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:00:30Z","timestamp":1784556030301,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.clindermatol.2023.08.016","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T20:48:23Z","timestamp":1693342103000},"page":"601-610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Assessment tools and phenotype classification for hidradenitis suppurativa"],"prefix":"10.1016","volume":"41","author":[{"given":"Nicole D.K.","family":"Koerts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klasiena","family":"Bouwman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette M.","family":"Prens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2023.08.016_bib0001","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0002","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000431175","article-title":"Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation","volume":"231","author":"Zouboulis","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0003","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jaad.2008.06.020","article-title":"Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies","volume":"59","author":"Revuz","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0004","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1468-3083.2009.03356.x","article-title":"Hidradenitis suppurativa","volume":"23","author":"Revuz","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0005","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjd.20954","article-title":"New insights in hidradenitis suppurativa from a population-based Dutch cohort: prevalence, smoking behaviour, socioeconomic status and comorbidities","volume":"186","author":"Prens","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0006","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jid.2020.10.014","article-title":"Unraveling the heterogeneity of hidradenitis suppurativa with phenotype schema","volume":"141","author":"Kirby","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0007","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/bjd.14475","article-title":"Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process","volume":"175","author":"Ingram","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0008","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/jid.2012.472","article-title":"Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study","volume":"133","author":"Canoui-Poitrine","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"5 suppl 1","key":"10.1016\/j.clindermatol.2023.08.016_bib0009","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.jaad.2015.07.047","article-title":"New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes","volume":"73","author":"van der Zee","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Clinical practice. Hidradenitis suppurativa","volume":"366","author":"Jemec","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0011","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.16672","article-title":"A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0012","series-title":"Dermatologic Surgery: Principles and Practice","first-page":"729","article-title":"Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach","author":"Hurley","year":"1989"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0013","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/bjd.17588","article-title":"Inter- and intrarater reliability of Hurley staging for hidradenitis suppurativa","volume":"181","author":"Ovadja","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0014","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjd.17716","article-title":"Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa","volume":"181","author":"Thorlacius","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000501771","article-title":"Could residents adequately assess the severity of hidradenitis suppurativa? Interrater and intrarater reliability assessment of major scoring systems","volume":"236","author":"W\u0142odarek","year":"2020","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0016","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/ced.14889","article-title":"Assessment of inter-rater reliability of clinical hidradenitis suppurativa outcome measures using ultrasonography","volume":"47","author":"Lyons","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0017","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1111\/jdv.15710","article-title":"Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicentre study","volume":"33","author":"Martorell","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0018","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2340\/00015555-2513","article-title":"Hurley staging refined: a proposal by the Dutch Hidradenitis Suppurativa Expert Group","volume":"97","author":"Horv\u00e1th","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0019","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/bjd.17508","article-title":"Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment","volume":"180","author":"Rondags","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0020","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/bjd.18235","article-title":"The refined Hurley classification: the inter-rater and intrarater reliability and face validity","volume":"181","author":"Prens","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0021","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jaad.2018.02.048","article-title":"Poor interrater reliability of hidradenitis suppurativa phenotypes","volume":"79","author":"van Straalen","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0022","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/bjd.17695","article-title":"Inter-rater reliability of phenotypes and exploratory genotype-phenotype analysis in inherited hidradenitis suppurativa","volume":"181","author":"Frew","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0023","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1159\/000518965","article-title":"Prevalence and clinical characteristics of hidradenitis suppurativa phenotypes in a large Dutch cohort","volume":"238","author":"Dudink","year":"2022","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0025","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0034","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archdermatol.2010.72","article-title":"Treatment of hidradenitis suppurativa with etanercept injection","volume":"146","author":"Adams","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0028","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0035","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/PRS.0b013e31821e6fb5","article-title":"Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study","volume":"128","author":"Highton","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0036","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2133.2011.10339.x","article-title":"A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa","volume":"165","author":"Miller","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0037","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/ijd.12936","article-title":"A prospective randomized controlled trial assessing the efficacy of adjunctive hyperbaric oxygen therapy in the treatment of hidradenitis suppurativa","volume":"55","author":"Yildiz","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0038","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0039","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial","volume":"80","author":"Vossen","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0041","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1684\/ejd.2020.3920","article-title":"Intense pulsed light treatment for hidradenitis suppurativa: a within-person randomized controlled trial","volume":"30","author":"Andersen","year":"2020","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0042","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0043","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","article-title":"Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial","volume":"156","author":"Bechara","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0044","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1159\/000518540","article-title":"LAight\u00ae therapy significantly enhances treatment efficacy of 16 weeks of topical clindamycin solution in Hurley I and II hidradenitis suppurativa: results from period A of RELIEVE, a multicenter randomized, controlled trial","volume":"238","author":"Schultheis","year":"2022","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0026","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0027","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0029","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1365-4632.2010.04545.x","article-title":"A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa","volume":"49","author":"Amano","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0030","first-page":"258","article-title":"AISI: a new disease severity assessment tool for hidradenitis suppurativa","volume":"27","author":"Chiricozzi","year":"2015","journal-title":"Wounds"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0031","first-page":"240","article-title":"Hidradenitis Suppurativa Area and Severity Index (HASI): a pilot study to develop a novel instrument to measure the physical signs of hidradenitis suppurativa","volume":"182","author":"Goldfarb","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0032","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/bjd.18244","article-title":"Severity and Area Score for Hidradenitis (SASH): a novel outcome measurement for hidradenitis suppurativa","volume":"182","author":"Kirby","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0033","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/bjd.19565","article-title":"Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R): psychometric property assessment","volume":"184","author":"Goldfarb","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1365-2133.2003.05390.x","article-title":"Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa","volume":"149","author":"Sartorius","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.08.016_bib0024","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","article-title":"Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity","volume":"161","author":"Sartorius","year":"2009","journal-title":"Br J Dermatol"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X23000950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X23000950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:21:06Z","timestamp":1760034066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X23000950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0738081X23000950"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2023.08.016","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment tools and phenotype classification for hidradenitis suppurativa","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2023.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}